Navigation Links
Allon Therapeutics to Present New Data at Leerink Swann Alzheimer's,Conference

VANCOUVER, British Columbia--(BUSINESS WIRE)--Apr 3, 2007 - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection Company(TM), announced today the publication of new preclinical data from additional confirmatory animal studies showing that Allon's product candidate AL-108 significantly reduces the accumulation of amyloid peptide and the hyperphosphorylation of tau protein in the brain, two pathological hallmarks of Alzheimer's.

Gordon McCauley, Allon's President and Chief Executive Officer, announced this publication to a conference in New York sponsored by investment bank Leerink Swann & Company entitled "A Mind is a Terrible Thing to Waste: Emerging Trends for Alzheimer's Disease." The invitation only event for institutional investors, venture capitalists and hedge fund managers who invest in the healthcare sector, highlights select companies developing Alzheimer's treatments.

"Our Alzheimer's program is based on this very compelling data showing that our compounds work on both of the classic hallmarks of Alzheimer's disease and the Phase II efficacy program is enrolling well," said McCauley. "We believe that we have implemented a sound and strategically balanced clinical plan for our compounds and we anticipate the results eagerly."

"Data published in The Journal of Molecular Neuroscience shows that AL-108 can modify disease progression in one of the most relevant models of Alzheimer's disease and our clinical development program is working to demonstrate this capability in human clinical trials," McCauley said.

McCauley said Allon is focused on developing drugs to treat processes underlying numerous neurodegenerative diseases and injury of the central nervous system. Drugs on the market today treat only the symptoms of these diseases and conditions.

Webcast and Conference location

Allon Therapeutics' presentation will take place on Tuesday, April 3, 2007 at 2:15pm Ea
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:3/27/2015)... March 27, 2015  Holographic Optical Technologies of ... of holographic medical imaging, is entering the world of ... Launching on April 20 th , 2015, the campaign ... The 8-inch and 22-inch displays will allow consumers to ... first time. In addition to the two displays, the ...
(Date:3/27/2015)... 27, 2015   Cypher Genomics, Inc., ... data showing that, compared to a panel of ... highly equivalent interpretations of whether certain genetic abnormalities ... in a fraction of the time. Cypher,s Mantis ... comprehensive genetic analysis in non-invasive prenatal testing (NIPT) ...
(Date:3/27/2015)... , March 27, 2015 XRpro Sciences, ... drug discovery and development services which features high ... pharmaceutical industry, announced financial results for the year ... C.  Tyson, Chairman of XRpro Sciences commented, "We ... transition from development stage to commercial stage in ...
Breaking Medicine Technology:Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4
... PARIS, October 24 Novexel, a speciality pharmaceutical,company ... antibiotics,designed to overcome the significant global problem of ... subject of five posters,at the joint annual meeting ... and the Infectious Disease Society of America (48th,annual ...
... - An Insulin Suppository Represents an Important Development ... Painless Alternative for Effective,Insulin Delivery, Oramed Pharmaceuticals, ... alternative drug delivery systems, announced today that it ... Council (MCC) to,begin conducting Phase 1A trials on ...
Cached Medicine Technology:Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting 2Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository 2Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository 3
(Date:3/28/2015)... 28, 2015 The California-based leading wig ... every customer shopping on UniWigs during the Easter Holidays ... a big promotion on April Fools’ Day. , As ... just around the corner. Easter Festival, with religious origins ... a major holiday after Christmas. The best wig provider, ...
(Date:3/28/2015)... IL (PRWEB) March 28, 2015 Centurion Service ... equipment auction on Thursday, April 2 at their Las Vegas ... Vegas, NV 89081. The sale, which consists of equipment from ... begin promptly at 9 a.m. PDT. , Buyers will ... and surgery equipment. “We are a one-stop-shop,” said Erik Tivin, ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... stiffness may not be necessary, according to research presented ... ( AOSSM ) Specialty Day. , “Our study compared ... with 25 who underwent an additional glenohumeral joint capsule ... surgery,” commented George Murrell MD, PhD, lead author from ...
(Date:3/28/2015)... 2015 Lately the student-athlete experience ... changes and proposals around the NCAA. In a March ... collegiate student-athletes across a spectrum of universities and sports ... challenges. The special panel consists of athletes who have ... from football, track and field, baseball, and volleyball. They ...
(Date:3/28/2015)... Aliso Viejo, California (PRWEB) March 28, 2015 ... have announced a new overlay entitled Scratches 5K from ... overlay grungy scratch effects to any media inside Final ... Film Studios. “StoryBoard Corporate saves time and is an ... any media using FCPX Overlay Scratches 5K's intuitive grunge ...
Breaking Medicine News(10 mins):Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2
... SCOTTSDALE, Ariz., Oct. 30 Changing Times,Vitamins, Inc., ... Las Vegas,has become a distributor for its primary ... tested, patent pending algae extract that has,been shown ... immune system. The beverage has no empty calories, ...
... Clinicians, Need for Detailed, Life-Saving Overdose,Information at the ... in November, TAMPA, Fla., Oct. 30 ... overdose references, Gold Standard Inc.,has re-launched ToxED ... toxicology reference addresses clinicians, need for,quick access to ...
... to acid in the mouth is the culprit, pediatric dentist ... its avalanche of candy is coming, making it the worst ... says a dentist who contends that parents can make a ... , "Parents need to know that frequency is far ...
... 30 Palomar Medical,Technologies, Inc. (Nasdaq: PMTI ... for cosmetic treatments, today announced financial,results for the ... the,quarter ended September 30, 2008 were $24.2 million, ... were royalty revenues, $1.0 million,were funded development revenues, ...
... Rally Residents to Eat Right, Move ... More and Milk Their Diets, WASHINGTON, Oct. ... of different fad diets -- which seem to go in and out ... out of three Americans -- including 22% of D.C. area residents --,remain ...
... SAN JUAN, Puerto Rico, Oct. 30 Triple-S,Management Corporation ... in,Puerto Rico, today announced record consolidated revenues for the ... million, or $0.29 per,diluted share, includes an after tax ... in net realized and unrealized losses on investments and,derivatives. ...
Cached Medicine News:Health News:Coors of Las Vegas Becomes New Distributor of RecoveryX 2Health News:Gold Standard Re-launches ToxED Clinical Toxicology Poisoning and Drug Overdose Reference 2Health News:Gold Standard Re-launches ToxED Clinical Toxicology Poisoning and Drug Overdose Reference 3Health News:Gold Standard Re-launches ToxED Clinical Toxicology Poisoning and Drug Overdose Reference 4Health News:Halloween Candy: It's Not How Much Kids Eat, It's When 2Health News:Halloween Candy: It's Not How Much Kids Eat, It's When 3Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 2Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 3Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 4Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 5Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 6Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 7Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 8Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 9Health News:Message to Washington D.C. Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Washington D.C. Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 2Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 3Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 4Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 5Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 6Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 7Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 8Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 9Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 10Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 11Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 12Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 13Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 14Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 15Health News:Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million 16
18 gauge curved. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Straight, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tu...
Sharp tip with cutting edge bent to 50 degrees fits 19 gauge or 20 gauge instrument port, 20 gauge instrument port, 20 gauge x 25 mm tapering to 25 gauge x 4.76 mm. 10 per box....
Developed for oculoplastic procedures for corneal and scleral protection. Dimensions enable protector to rest on the sclera and not on the cornea. Easily removed with Bishop-Harmon Forceps. Individua...
Medicine Products: